Beta Thalassemia Testing Market

Beta Thalassemia Testing Market
surrounding the fetus. Blood from the developing fetus can also be as good source of sample for
detecting thalassemia but aspirating blood sample may cause some damage to a developing fetus, hence
taking of amniotic fluid samples is generally preferred. Chorionic Villus sampling (CVS) is another
technique of diagnosing genetic problems in the fetus. Sample is collected from the placental tissue or
chorionic villus. There is risk of miscarriage involved with every prenatal test. Preimplantation genetic
diagnosis (PGD) is a new procedure that may be performed on embryos which are produced by in vitro
fertilization. This test is performed on the embryos which are produced artificially and also allows parents
to carry and implant only those embryos that are not carrying the mutated thalassemia genes.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1738
Most commonly prone area for beta thalassemia are Mediterranean countries, African countries, and
Southeast Asian countries. Thalassemia trait almost affects 5% to 30% of the population in these ethnic
groups. The growing population in these countries act as the drivers for beta thalassemia testing kit
market. A number of factors such as high implementation cost of sophisticated clinical and preclinical
imaging systems, High cost of maintenance, low life span of accessories used are restricting the growth of
the global imaging market.
Based on technology, the beta thalassemia testing Market is segmented into the following:
©2015 Future Market Insights, All Rights Reserved 5